High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites

This study provides novel insight into the molecular pathogenesis of IP-DLBCL and indicates that anti-CD37 therapies will be more beneficial for DLBCL patients without CD37 mutations.

Source: Blood - September 18, 2019 Category: Hematology Authors: Elfrink, S., de Winde, C. M., van den Brand, M., Berendsen, M., Roemer, M. G. M., Arnold, F., Janssen, L., van der Schaaf, A., Jansen, E., Groenen, P. J. T. A., Eijkelenboom, A., Stevens, W., Hess, C. J., van Krieken, J. H., Vermaat, J. S. P., Cleven, A. Tags: Lymphoid Neoplasia, Brief Reports Source Type: research